Think of the Neurokinin-1 Antagonists as Equally Efficacious
Rolapitant (Varubi) will compete with older neurokinin-1 antagonists to prevent chemotherapy-induced nausea and vomiting.
It will join oral aprepitant and IV fosaprepitant (Emend, etc) and the combo of netupitant and the 5-HT3 antagonist palonosetron (Akynzeo).
We know that highly emetogenic chemotherapy (cisplatin, etc) requires using a three-drug regimen of a neurokinin-1 (NK-1) antagonist... 5-HT3 antagonist (ondansetron, etc)...and dexamethasone.
Get unlimited access through an Enterprise license
Hospital Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 300+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Not sold to individuals